Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 78.85 EUR 0.45%
Market Cap: 1.4B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Intrinsic Value

The intrinsic value of one PHM stock under the Base Case scenario is 89.32 EUR. Compared to the current market price of 78.85 EUR, Pharma Mar SA is Undervalued by 12%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHM Intrinsic Value
89.32 EUR
Undervaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Pharma Mar SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for PHM cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about PHM?
Bearish
Neutral
Bullish

Fundamental Analysis

78.85 EUR
+0.45%
+0.45%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Pharma Mar SA
ES
Biotechnology
Market Cap
1.4B EUR
IPO
Nov 2, 2015
Employees
477
Spain
Market Cap
1.4B EUR
Industry
Biotechnology
IPO
Nov 2, 2015
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Pharma Mar SA

Provide an overview of the primary business activities
of Pharma Mar SA.

What unique competitive advantages
does Pharma Mar SA hold over its rivals?

What risks and challenges
does Pharma Mar SA face in the near future?

Summarize the latest earnings call
of Pharma Mar SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Pharma Mar SA.

Provide P/S
for Pharma Mar SA.

Provide P/E
for Pharma Mar SA.

Provide P/OCF
for Pharma Mar SA.

Provide P/FCFE
for Pharma Mar SA.

Provide P/B
for Pharma Mar SA.

Provide EV/S
for Pharma Mar SA.

Provide EV/GP
for Pharma Mar SA.

Provide EV/EBITDA
for Pharma Mar SA.

Provide EV/EBIT
for Pharma Mar SA.

Provide EV/OCF
for Pharma Mar SA.

Provide EV/FCFF
for Pharma Mar SA.

Provide EV/IC
for Pharma Mar SA.

Show me price targets
for Pharma Mar SA made by professional analysts.

What are the Revenue projections
for Pharma Mar SA?

How accurate were the past Revenue estimates
for Pharma Mar SA?

What are the Net Income projections
for Pharma Mar SA?

How accurate were the past Net Income estimates
for Pharma Mar SA?

What are the EPS projections
for Pharma Mar SA?

How accurate were the past EPS estimates
for Pharma Mar SA?

What are the EBIT projections
for Pharma Mar SA?

How accurate were the past EBIT estimates
for Pharma Mar SA?

Compare the revenue forecasts
for Pharma Mar SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharma Mar SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharma Mar SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharma Mar SA compared to its peers.

Compare the P/E ratios
of Pharma Mar SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharma Mar SA with its peers.

Analyze the financial leverage
of Pharma Mar SA compared to its main competitors.

Show all profitability ratios
for Pharma Mar SA.

Provide ROE
for Pharma Mar SA.

Provide ROA
for Pharma Mar SA.

Provide ROIC
for Pharma Mar SA.

Provide ROCE
for Pharma Mar SA.

Provide Gross Margin
for Pharma Mar SA.

Provide Operating Margin
for Pharma Mar SA.

Provide Net Margin
for Pharma Mar SA.

Provide FCF Margin
for Pharma Mar SA.

Show all solvency ratios
for Pharma Mar SA.

Provide D/E Ratio
for Pharma Mar SA.

Provide D/A Ratio
for Pharma Mar SA.

Provide Interest Coverage Ratio
for Pharma Mar SA.

Provide Altman Z-Score Ratio
for Pharma Mar SA.

Provide Quick Ratio
for Pharma Mar SA.

Provide Current Ratio
for Pharma Mar SA.

Provide Cash Ratio
for Pharma Mar SA.

What is the historical Revenue growth
over the last 5 years for Pharma Mar SA?

What is the historical Net Income growth
over the last 5 years for Pharma Mar SA?

What is the current Free Cash Flow
of Pharma Mar SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharma Mar SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharma Mar SA

Current Assets 238m
Cash & Short-Term Investments 144.4m
Receivables 33.7m
Other Current Assets 59.9m
Non-Current Assets 95.1m
Long-Term Investments 4.6m
PP&E 57.7m
Intangibles 1.2m
Other Non-Current Assets 31.6m
Current Liabilities 89.4m
Accounts Payable 35.2m
Accrued Liabilities 410k
Short-Term Debt 5.6m
Other Current Liabilities 48.3m
Non-Current Liabilities 61.5m
Long-Term Debt 42.2m
Other Non-Current Liabilities 19.3m
Efficiency

Earnings Waterfall
Pharma Mar SA

Revenue
167m EUR
Cost of Revenue
-9.3m EUR
Gross Profit
157.7m EUR
Operating Expenses
-161.4m EUR
Operating Income
-3.7m EUR
Other Expenses
4.3m EUR
Net Income
622k EUR

Free Cash Flow Analysis
Pharma Mar SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PHM Profitability Score
Profitability Due Diligence

Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive 3-Year Average ROE
Positive Net Income
58/100
Profitability
Score

Pharma Mar SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

PHM Solvency Score
Solvency Due Diligence

Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Negative Net Debt
Short-Term Solvency
63/100
Solvency
Score

Pharma Mar SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHM Price Targets Summary
Pharma Mar SA

Wall Street analysts forecast PHM stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHM is 76.59 EUR with a low forecast of 29.9 EUR and a high forecast of 99.75 EUR.

Lowest
Price Target
29.9 EUR
62% Downside
Average
Price Target
76.59 EUR
3% Downside
Highest
Price Target
99.75 EUR
27% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PHM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PHM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one PHM stock?

The intrinsic value of one PHM stock under the Base Case scenario is 89.32 EUR.

Is PHM stock undervalued or overvalued?

Compared to the current market price of 78.85 EUR, Pharma Mar SA is Undervalued by 12%.

Back to Top